Gerresheimer (GXI) Q2 2024 earnings summary

Executive summary

• Q2 2024 results were resilient, with organic revenue up 0.7% and adjusted EBITDA up 0.8% year-over-year, despite temporary destocking in the vial business; strong offsetting performance in Plastics & Devices and continued margin expansion in that segment.

• The company’s broad portfolio and strategic focus on high-value solutions and medical devices underpin its competitive position and sustainable growth.

• The acquisition of Bormioli Pharma, announced in May 2024 for an enterprise value of €800m, is expected to significantly strengthen both the base and high-value solutions business, especially in plastics and system integration.

• Guidance for 2024 and 2025 is confirmed, with expectations for a strong H2 2024 as destocking fades and new production lines ramp up.

• Net income for H1 2024 was €46.4m, down from €49.1m in the prior year, with adjusted EPS at €1.90 versus €2.02.

Financial highlights

• Q2 2024 revenues were €502.4m, up 0.6% year-over-year, with organic revenue growth of 4.7%.

• Adjusted EBITDA for Q2 2024 was €107.3m, with organic adjusted EBITDA growth of 4.8% and margin stable at 21.6%.

• Adjusted EPS for Q2 2024 was €1.24, down from €1.30 in Q2 2023, mainly due to the dilutive effect of the April 2023 capital increase.

• H1 2024 revenues were €968.5m, with organic growth of 1.7% year-over-year; adjusted EBITDA was €188.2m, up 2.9%.

• Free cash flow before M&A for 6M 2024 was -€148.0m, mainly due to higher capital expenditure; net financial debt increased to €1,097.2m, with adjusted EBITDA leverage at 2.5x.

Outlook and guidance

• Revenue growth for 2024 is expected at the low end of the 5%-10% guidance range due to lingering destocking effects.

• Adjusted EBITDA for 2024 is projected between €430 million and €450 million, with adjusted EPS growth of 8%-12%.

• Q3 is expected to show improvement over H1, with Q4 delivering the strongest growth as new lines ramp up and destocking fades.

• Guidance for 2025 and the mid-term remains unchanged, with organic revenue CAGR ≥10% and adjusted EBITDA margin 23–25%.

• Adjusted EPS for 2024 is projected at €4.62, up from €4.22 in 2023.